mycophenolate mofetil
Phase 1Completed 0 watching 0 views this week💤 Quiet
33
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Congenital Urological Abnormalities
Conditions
Congenital Urological Abnormalities
Trial Timeline
Mar 1, 2002 → Aug 1, 2007
NCT ID
NCT00193635About mycophenolate mofetil
mycophenolate mofetil is a phase 1 stage product being developed by Roche for Congenital Urological Abnormalities. The current trial status is completed. This product is registered under clinical trial identifier NCT00193635. Target conditions include Congenital Urological Abnormalities.
Hype Score Breakdown
Clinical
10
Activity
5
Company
10
Novelty
3
Community
2
Clinical Trials (8)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01213394 | Phase 3 | Terminated |
| NCT01014442 | Phase 3 | Completed |
| NCT00333437 | Pre-clinical | Completed |
| NCT00187941 | Phase 1 | Completed |
| NCT00788567 | Phase 3 | Completed |
| NCT00166244 | Approved | Completed |
| NCT00199667 | Approved | UNKNOWN |
| NCT00193635 | Phase 1 | Completed |
Competing Products
20 competing products in Congenital Urological Abnormalities
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Tideglusib | AMO Pharma | Pre-clinical | 15 |
| Tideglusib + Placebo | AMO Pharma | Phase 2/3 | 57 |
| Tideglusib | AMO Pharma | Phase 2/3 | 57 |
| EDIT-101 | Editas Medicine | Phase 1/2 | 33 |
| Tildacerfont/Placebo | Spruce Biosciences | Phase 2 | 44 |
| SPR001 | Spruce Biosciences | Phase 2 | 44 |
| SPR001 | Spruce Biosciences | Phase 2 | 44 |
| Tildacerfont/Placebo | Spruce Biosciences | Phase 2 | 44 |
| Tildacerfont | Spruce Biosciences | Phase 2 | 44 |
| KW-3357 | Kyowa Kirin | Phase 1 | 33 |
| Pasireotide 0.6Mg Solution for Injection + Saline Solution | Novartis | Phase 2 | 52 |
| Sandostatine LP | Novartis | Phase 2 | 52 |
| turoctocog alfa + turoctocog alfa | Novo Nordisk | Phase 3 | 76 |
| catridecacog + recombinant factor XIII | Novo Nordisk | Phase 1 | 32 |
| activated recombinant human factor VII | Novo Nordisk | Phase 2 | 51 |
| turoctocog alfa pegol | Novo Nordisk | Phase 3 | 76 |
| recombinant factor XIII | Novo Nordisk | Pre-clinical | 22 |
| activated recombinant human factor VII, long acting + activated recombinant human factor VII, long acting | Novo Nordisk | Phase 1 | 32 |
| Advate® + turoctocog alfa | Novo Nordisk | Phase 1 | 32 |
| nonacog beta pegol | Novo Nordisk | Phase 3 | 76 |